Peter Stärkel1, Bernd Schnabl2,3, Bei Gao4, Sonja Lang4, Yi Duan4,5, Yanhan Wang4,5, Debbie L Shawcross6, Alexandre Louvet7, Philippe Mathurin7, Samuel B Ho4,5. 1. St. Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium. 2. Department of Medicine, University of California San Diego, La Jolla, CA, USA. beschnabl@ucsd.edu. 3. Department of Medicine, VA San Diego Healthcare System, San Diego, CA, USA. beschnabl@ucsd.edu. 4. Department of Medicine, University of California San Diego, La Jolla, CA, USA. 5. Department of Medicine, VA San Diego Healthcare System, San Diego, CA, USA. 6. Institute of Liver Studies, King's College London School of Medicine at King's College Hospital, King's College Hospital, London, UK. 7. Service des Maladies de L'appareil Digestif et Unité INSERM, Hôpital Huriez, Lille, France.
Abstract
BACKGROUND: Alcohol-related liver disease is one of the most prevalent chronic liver diseases worldwide. Mechanisms involved in the pathogenesis of alcohol-related liver disease are not well understood. Oxylipins play a crucial role in numerous biological processes and pathological conditions. Nevertheless, oxylipins are not well studied in alcohol-related liver disease. AIMS: (1) To characterize the patterns of bioactive ω-3 and ω-6 polyunsaturated fatty acid metabolites in alcohol use disorder and alcoholic hepatitis patients and (2) to identify associations of serum oxylipins with clinical parameters in patients with alcohol-related liver disease. METHODS: We performed a comprehensive liquid chromatography with tandem mass spectrometry (LC-MS/MS) analysis of serum and fecal oxylipins derived from ω-6 arachidonic acid, ω-3 eicosapentaenoic acid, and docosahexaenoic acid in a patient cohort with alcohol-related liver disease. RESULTS: Our results show profound alterations in the serum oxylipin profile of patients with alcohol use disorder and alcoholic hepatitis compared to nonalcoholic controls. Spearman correlation of the oxylipins with clinical parameters shows a link between different serum oxylipins and intestinal permeability, aspartate aminotransferase, bilirubin, albumin, international normalized ratio, platelet count, steatosis, fibrosis and model for end-stage liver disease score. Especially, higher level of serum 20-HETE was significantly associated with decreased albumin, increased hepatic steatosis, polymorphonuclear infiltration, and 90-day mortality. CONCLUSIONS: Patients with alcohol-related liver disease have different oxylipin profiles. Future studies are required to confirm oxylipins as disease biomarker or to connect oxylipins to disease pathogenesis.
BACKGROUND: Alcohol-related liver disease is one of the most prevalent chronic liver diseases worldwide. Mechanisms involved in the pathogenesis of alcohol-related liver disease are not well understood. Oxylipins play a crucial role in numerous biological processes and pathological conditions. Nevertheless, oxylipins are not well studied in alcohol-related liver disease. AIMS: (1) To characterize the patterns of bioactive ω-3 and ω-6 polyunsaturated fatty acid metabolites in alcohol use disorder and alcoholic hepatitis patients and (2) to identify associations of serum oxylipins with clinical parameters in patients with alcohol-related liver disease. METHODS: We performed a comprehensive liquid chromatography with tandem mass spectrometry (LC-MS/MS) analysis of serum and fecal oxylipins derived from ω-6 arachidonic acid, ω-3 eicosapentaenoic acid, and docosahexaenoic acid in a patient cohort with alcohol-related liver disease. RESULTS: Our results show profound alterations in the serum oxylipin profile of patients with alcohol use disorder and alcoholic hepatitis compared to nonalcoholic controls. Spearman correlation of the oxylipins with clinical parameters shows a link between different serum oxylipins and intestinal permeability, aspartate aminotransferase, bilirubin, albumin, international normalized ratio, platelet count, steatosis, fibrosis and model for end-stage liver disease score. Especially, higher level of serum 20-HETE was significantly associated with decreased albumin, increased hepatic steatosis, polymorphonuclear infiltration, and 90-day mortality. CONCLUSIONS: Patients with alcohol-related liver disease have different oxylipin profiles. Future studies are required to confirm oxylipins as disease biomarker or to connect oxylipins to disease pathogenesis.
Authors: Stephanie P B Caligiuri; Mihir Parikh; Aleksandra Stamenkovic; Grant N Pierce; Harold M Aukema Journal: Am J Physiol Heart Circ Physiol Date: 2017-08-11 Impact factor: 4.733
Authors: Ariel E Feldstein; Rocio Lopez; Tarek Abu-Rajab Tamimi; Lisa Yerian; Yoon-Mi Chung; Michael Berk; Renliang Zhang; Thomas M McIntyre; Stanley L Hazen Journal: J Lipid Res Date: 2010-07-14 Impact factor: 5.922
Authors: Jeremy P Koelmel; Michael P Napolitano; Candice Z Ulmer; Vasilis Vasiliou; Timothy J Garrett; Richard A Yost; M N V Prasad; Krystal J Godri Pollitt; John A Bowden Journal: Metabolomics Date: 2020-04-19 Impact factor: 4.290
Authors: Yi Duan; Cristina Llorente; Sonja Lang; Katharina Brandl; Huikuan Chu; Lu Jiang; Richard C White; Thomas H Clarke; Kevin Nguyen; Manolito Torralba; Yan Shao; Jinyuan Liu; Adriana Hernandez-Morales; Lauren Lessor; Imran R Rahman; Yukiko Miyamoto; Melissa Ly; Bei Gao; Weizhong Sun; Roman Kiesel; Felix Hutmacher; Suhan Lee; Meritxell Ventura-Cots; Francisco Bosques-Padilla; Elizabeth C Verna; Juan G Abraldes; Robert S Brown; Victor Vargas; Jose Altamirano; Juan Caballería; Debbie L Shawcross; Samuel B Ho; Alexandre Louvet; Michael R Lucey; Philippe Mathurin; Guadalupe Garcia-Tsao; Ramon Bataller; Xin M Tu; Lars Eckmann; Wilfred A van der Donk; Ry Young; Trevor D Lawley; Peter Stärkel; David Pride; Derrick E Fouts; Bernd Schnabl Journal: Nature Date: 2019-11-13 Impact factor: 49.962
Authors: Luca Maccioni; Bei Gao; Sophie Leclercq; Boris Pirlot; Yves Horsmans; Philippe De Timary; Isabelle Leclercq; Derrick Fouts; Bernd Schnabl; Peter Stärkel Journal: Gut Microbes Date: 2020-06-26
Authors: Dennis Warner; Vatsalya Vatsalya; Kara H Zirnheld; Jeffrey B Warner; Josiah E Hardesty; John C Umhau; Craig J McClain; Krishnarao Maddipati; Irina A Kirpich Journal: Hepatol Commun Date: 2021-02-09
Authors: Bei Gao; Yi Duan; Sonja Lang; Dinesh Barupal; Tsung-Chin Wu; Luis Valdiviez; Bryan Roberts; Ying Yng Choy; Tong Shen; Gregory Byram; Ying Zhang; Sili Fan; Benjamin Wancewicz; Yan Shao; Kevin Vervier; Yanhan Wang; Rongrong Zhou; Lu Jiang; Shilpa Nath; Rohit Loomba; Juan G Abraldes; Ramon Bataller; Xin M Tu; Peter Stärkel; Trevor D Lawley; Oliver Fiehn; Bernd Schnabl Journal: Hepatol Commun Date: 2020-06-19
Authors: Bei Gao; Atoosa Emami; Rongrong Zhou; Sonja Lang; Yi Duan; Yanhan Wang; Lu Jiang; Rohit Loomba; David A Brenner; Peter Stärkel; Bernd Schnabl Journal: Front Physiol Date: 2020-04-24 Impact factor: 4.755